MedTrace Logo

Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy

NCT03192826 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2019-07-16

Study results available
· View outcomes & findings →

Summary

To compare the efficacy of a Brinzolamide/Brimonidine fixed combination (FC) with Brimonidine 0.2% in preventing intraocular pressure (IOP) elevations after neodymium: yttrium-aluminum-garnet (Nd:YAG) laser posterior capsulotomy.

Conditions

Interventions

DRUG

Brinzolamide/Brimonidine FC

1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy

DRUG

Brimonidine 0.2%

1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy

DRUG

Artificial tears

1 drop of artificial tears 1 hour before Nd-YAG capsulotomy

Sponsors & Collaborators

  • University Hospital of Patras

    lead OTHER

Principal Investigators

  • Constantinos Georgakopoulos, MD, PhD · University Hospital of Patras

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-20
Primary Completion
2017-07-08
Completion
2017-07-08
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03192826 on ClinicalTrials.gov